At Shriners Hospitals for Children—Cincinnati, the health and safety of our patients, families, volunteers and staff is our top priority. With the rapidly evolving situation regarding coronavirus (COVID-19,) we are closely monitoring local health departments and The Centers for Disease Control and Prevention (CDC,) and are actively following their recommendations.

We are working diligently to reschedule appointments postponed during the quarantine. We also understand you may feel some anxiety about bringing your child into the hospital. Our plans to restart routine care have been thoughtfully developed and implemented to keep everyone safe. We are also scheduling some appointments for new patients. If you have any questions, please call the hospital at 855-206-2096.

Families that have appointments of any kind are asked to arrive with ONLY ONE parent or guardian and no additional family members or guests.

When you arrive for your appointment, if you and your child are not already wearing a mask, you will receive one. You will both be screened for illness and will notice new safety precautions in place to promote clean hands, a clean environment, and social distancing.

We are here for you, and look forward to seeing you soon.

Ambikaipakan Balasubramaniam, Ph.D.

Research interests

Role of polypeptide hormones and phosphodiesterase enzymes in muscle cachexia, inflammation and hyperlactacidemia in burn injury; Role of polypeptide hormones in obesity


Dr. Balasubramaniam joined UC as a postdoctoral fellow in 1981, and has risen through the ranks and now holds a Tenured Professor appointment in the Department of Surgery with joint appointments in Cincinnati VA Medical Center and Shriners Hospitals for Children. He studies Polypeptide Hormones in Health & Disease, currently focusing on their role in obesity, cachexia and critical illness. He has to his credit: 1) >160 peer reviewed papers which have been cited > 4,600 times, 28 book chapters and > 90 presentations/abstracts. 2) has been successful in obtaining extramural funding from NIH, VA, Shriners Hospital for Children or Industries; 3) has been awarded 10 patents and received upfront licensing fee for few of his patents; 4) honored several times as one of the University of Cincinnati Faculty Inventor; recognized with University of Cincinnati Faculty achievement award in1996; NATO Collaborative Research Award; The Wellcome Trust Travel Award; 5) served as a member of NIH study sections, Editorial Boards, Organizing Committees of Neuropeptide Y International Meetings (FL, Japan, Australia) and Chaired Sessions; Reviewed publications for several Journals; Edited Books; has served University of Cincinnati and VA Committees.

Education and training

University of Colombo, Sri Lanka, B. Sc. (Hons), 1971-75, Chemistry
University of Exeter, UK, Ph. D., 1976-79, Chemistry
University of Iowa, Iowa City, IA, Postdoctoral Fellow, 1979-80, Bio-Inorganic Chemistry
University of Illinois Medical Center, Chicago, IL, Postdoctoral Fellow, 1980-81, Peptide Chemistry
University of Cincinnati Medical Center, Chicago, IL, Postdoctoral Fellow, 1981-83, Polypeptide Hormones

Publications (2014-present):

Parker MS, Sah R, Balasubramaniam A, Park E, Sallee FR, Parker SL. Dimers of G-protein coupling receptors as versatile storage and response units. International Journal of Molecular Sciences, 2014; 15:4856-77.

Joshi R, Kadeer N, , Sheriff S, Friend LA, James JH, Balasubramaniam A. Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through a PDE4/cAMP/Epac/PI3K/Akt pathway. Mol Cell Endocrinol, 2014;393:152-163

Parker MS, Sah R, Balasubramaniam A, Sallee FR, Park EA, Parker SL. On the expansion of ribosomal proteins and RNAs in eukaryotes. Amino Acids 03/2014.

Sheriff S, Kadeer N, Friend LA, James JH, Alexander WJ, Balasubramaniam A. Des-Acyl-Ghrelin (DAG) Normalizes Hyperlactacidemia and Improves Survival in a Lethal Rat Model of Burn Trauma. Peptides 2014; 60:1-7.

Wang B, Sheriff S, Balasubramaniam A, Kennedy MA. NMR based metabonomics study of NPY Y2 Receptor activation in SK-N-BE2, a human neuroblastoma cell line. Metabolomics 2015;11:1-12.

Portelli J, Meurs A, Bihel F, Hammoud H, Schmitt M, De Kock J, Utard V, Humbert JP, Bertin I, Buffel I, Coppens J, Tourwe D, Maes V, De Prins A, Vanhaecke T, Massie A, Balasubramaniam A, Boon P, Bourguignon JJ, Simonin F, Smolders I. Neuropeptide FF receptors as novel targets for limbic seizure attenuation. Neuropharmacology. 2015;415-23.

Joshi R, Kadeer N, Sheriff S, Friend LA, James JH, Balasubramaniam A. Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/ PI3K/Akt pathway. Mol Cell Endocrinol. 2014;393(1-2):152-63.

Sheriff S, Rizvi TA, Khan SA, Pathrose P, Kadeer N, Amlal H, Herzog H, Balasubramaniam A. Up-regulation of Neuropeptide Y (NPY) Y5R protein in human breast carcinoma: immunohistochemical study. Neuropeptides. Revised & resubmitted.

Sheriff S, Schurdak J, Rizvi T, Benoit S, Balasubramaniam A. Neuropeptide Y activates ERK via modulation of downstream elements, Rap1, Ras and Raf1 in a hypothalamic cell line: Hypothalamic PKA- and ERK-pathways mediate NPY-induced feeding in rats. in preparation.


Principal Investigator, Shriners Hospitals for Children grant entitled “PDE4 inhibitors for combating burn-induced inflammation and muscle cachexia”, $1,327,286, 01/01/2013 – 12/31/2017


Ambikaipakan Balasubramaniam, Ph.D.
[email protected]

Translate »